FDA approves supplement 35 for Eisai's Lenvima
The efficacy-related application update for the oral cancer drug lenvatinib mesylate was approved with a standard review priority.
Drugs@FDA
Latest
2 stories
Sign inSign in2 stories
The efficacy-related application update for the oral cancer drug lenvatinib mesylate was approved with a standard review priority.
Drugs@FDA